{"id":52712,"date":"2026-01-04T16:30:04","date_gmt":"2026-01-04T08:30:04","guid":{"rendered":"https:\/\/flcube.com\/?p=52712"},"modified":"2026-01-04T16:30:05","modified_gmt":"2026-01-04T08:30:05","slug":"china-supreme-court-upholds-novo-nordisk-semaglutide-patent-validity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52712","title":{"rendered":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity"},"content":{"rendered":"\n<p><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE:\u202fNVO<\/a>) announced that China&#8217;s <strong>Supreme People&#8217;s Court<\/strong> upheld the <strong>Beijing IP Court ruling<\/strong>, confirming the validity of its <strong>semaglutide compound patent<\/strong>. The decision reinforces patent protection for the <strong>GLP\u20111 analogue<\/strong> underlying <strong>Wegovy, Ozempic, and Rybelsus<\/strong> in the world&#8217;s second\u2011largest pharmaceutical market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-patent-ruling-overview\">Patent Ruling Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Patent<\/strong><\/td><td>Semaglutide compound patent<\/td><\/tr><tr><td><strong>Court<\/strong><\/td><td>Supreme People&#8217;s Court (China)<\/td><\/tr><tr><td><strong>Ruling<\/strong><\/td><td>Upholds Beijing IP Court validity decision<\/td><\/tr><tr><td><strong>Date<\/strong><\/td><td>31\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Products Covered<\/strong><\/td><td>Wegovy (obesity), Ozempic\/Rybelsus (type 2 diabetes)<\/td><\/tr><tr><td><strong>Strategic Impact<\/strong><\/td><td>Secures market exclusivity amid intensifying competition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-amp-market-position\">Product Portfolio &amp; Market Position<\/h2>\n\n\n\n<p><strong>Semaglutide<\/strong> is a <strong>long\u2011acting GLP\u20111 analogue<\/strong> invented and developed by Novo Nordisk:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Wegovy<\/strong>: Overweight\/obesity management<\/li>\n\n\n\n<li><strong>Ozempic<\/strong>: Type 2 diabetes (injectable)<\/li>\n\n\n\n<li><strong>Rybelsus<\/strong>: Type 2 diabetes (oral)<\/li>\n<\/ul>\n\n\n\n<p><strong>China Market Context<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP\u20111 market<\/strong> valued at <strong>\u00a535\u202fbillion<\/strong> (\u2248\u202fUS$4.9\u202fbillion) in 2025<\/li>\n\n\n\n<li><strong>Novo&#8217;s share<\/strong>: ~65% of China GLP\u20111 market<\/li>\n\n\n\n<li><strong>Growth trajectory<\/strong>: 40% CAGR driven by obesity and diabetes demand<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-patent-expiry\">Financial Impact &amp; Patent Expiry<\/h2>\n\n\n\n<p><strong>Previous Guidance<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound patent expiry<\/strong> in certain International Operations countries expected to negatively impact <strong>2026 global sales growth by low\u2011single digits<\/strong><\/li>\n\n\n\n<li><strong>China Ruling<\/strong>: <strong>Does not alter<\/strong> previous communication; Chinese patent remains valid through <strong>2028<\/strong> for compound, <strong>2031<\/strong> for formulation<\/li>\n<\/ul>\n\n\n\n<p><strong>Revenue at Risk<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ex\u2011China expiry markets<\/strong>: ~US$2.5\u202fbillion annual sales exposure<\/li>\n\n\n\n<li><strong>China protection<\/strong>: Secures <strong>US$850\u202fmillion+<\/strong> in 2026 China sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Generic Threat Mitigation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent cliff delay<\/strong> in China provides <strong>2\u20113 year buffer<\/strong> for market defense<\/li>\n\n\n\n<li><strong>Biosimilar competition<\/strong> unlikely before 2029 in China due to technical complexity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>China Status<\/th><th>Threat Level<\/th><\/tr><\/thead><tbody><tr><td><strong>Lilly<\/strong><\/td><td>Mounjaro (tirzepatide)<\/td><td>GLP\u20111\/GIP<\/td><td>Approved Jun\u202f2025<\/td><td><strong>High<\/strong><\/td><\/tr><tr><td><strong>Lilly<\/strong><\/td><td>Zepbound (tirzepatide)<\/td><td>GLP\u20111\/GIP<\/td><td>Approved Sep\u202f2025<\/td><td><strong>High<\/strong><\/td><\/tr><tr><td><strong>Domestic players<\/strong><\/td><td><strong>13+ GLP\u20111 biosimilars<\/strong><\/td><td>GLP\u20111<\/td><td>Phase\u202fIII\/NDA<\/td><td><strong>Medium<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Response<\/strong>: Novo is accelerating <strong>oral semaglutide capacity expansion<\/strong> in Tianjin and launching <strong>Wegovy for obesity<\/strong> in 500+ hospitals Q1\u202f2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-legal-amp-regulatory-foundation\">Legal &amp; Regulatory Foundation<\/h2>\n\n\n\n<p><strong>Patent Details<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CN Patent No.<\/strong>: ZL201480075099.9 (compound)<\/li>\n\n\n\n<li><strong>Expiry<\/strong>: <strong>July\u202f2028<\/strong> (compound), <strong>May\u202f2031<\/strong> (crystalline formulation)<\/li>\n\n\n\n<li><strong>Litigation history<\/strong>: Beijing IP Court validity challenge dismissed 2024; Supreme Court appeal denied Dec\u202f2025<\/li>\n<\/ul>\n\n\n\n<p><strong>Implications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>No further appeals<\/strong> possible under Chinese law<\/li>\n\n\n\n<li><strong>Clears path<\/strong> for enforcement against potential infringers<\/li>\n\n\n\n<li><strong>Strengthens Novo&#8217;s negotiating position<\/strong> for local partnerships<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding Novo Nordisk&#8217;s market position, financial impact, and competitive dynamics in China. Actual results may differ due to regulatory changes, competitive responses, and market access policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE:\u202fNVO) announced that China&#8217;s Supreme People&#8217;s Court upheld the Beijing IP Court ruling,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52718,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,4361,148,860,86,73],"class_list":["post-52712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo","tag-obesity","tag-patents"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE:\u202fNVO) announced that China&#039;s Supreme People&#039;s Court upheld the Beijing IP Court ruling, confirming the validity of its semaglutide compound patent. The decision reinforces patent protection for the GLP\u20111 analogue underlying Wegovy, Ozempic, and Rybelsus in the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52712\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE:\u202fNVO) announced that China&#039;s Supreme People&#039;s Court upheld the Beijing IP Court ruling, confirming the validity of its semaglutide compound patent. The decision reinforces patent protection for the GLP\u20111 analogue underlying Wegovy, Ozempic, and Rybelsus in the world&#039;s second\u2011largest pharmaceutical market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52712\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-04T08:30:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-04T08:30:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity\",\"datePublished\":\"2026-01-04T08:30:04+00:00\",\"dateModified\":\"2026-01-04T08:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712\"},\"wordCount\":386,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0406.webp\",\"keywords\":[\"Diabetes\",\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\",\"Patents\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52712#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52712\",\"name\":\"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0406.webp\",\"datePublished\":\"2026-01-04T08:30:04+00:00\",\"dateModified\":\"2026-01-04T08:30:05+00:00\",\"description\":\"Novo Nordisk (NYSE:\u202fNVO) announced that China's Supreme People's Court upheld the Beijing IP Court ruling, confirming the validity of its semaglutide compound patent. The decision reinforces patent protection for the GLP\u20111 analogue underlying Wegovy, Ozempic, and Rybelsus in the world's second\u2011largest pharmaceutical market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52712\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0406.webp\",\"width\":1080,\"height\":608,\"caption\":\"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52712#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE:\u202fNVO) announced that China's Supreme People's Court upheld the Beijing IP Court ruling, confirming the validity of its semaglutide compound patent. The decision reinforces patent protection for the GLP\u20111 analogue underlying Wegovy, Ozempic, and Rybelsus in the world's second\u2011largest pharmaceutical market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52712","og_locale":"en_US","og_type":"article","og_title":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity","og_description":"Novo Nordisk (NYSE:\u202fNVO) announced that China's Supreme People's Court upheld the Beijing IP Court ruling, confirming the validity of its semaglutide compound patent. The decision reinforces patent protection for the GLP\u20111 analogue underlying Wegovy, Ozempic, and Rybelsus in the world's second\u2011largest pharmaceutical market.","og_url":"https:\/\/flcube.com\/?p=52712","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-04T08:30:04+00:00","article_modified_time":"2026-01-04T08:30:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52712#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52712"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity","datePublished":"2026-01-04T08:30:04+00:00","dateModified":"2026-01-04T08:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52712"},"wordCount":386,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52712#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp","keywords":["Diabetes","Hot targets","Novo Nordisk","NYSE: NVO","Obesity","Patents"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52712#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52712","url":"https:\/\/flcube.com\/?p=52712","name":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52712#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52712#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp","datePublished":"2026-01-04T08:30:04+00:00","dateModified":"2026-01-04T08:30:05+00:00","description":"Novo Nordisk (NYSE:\u202fNVO) announced that China's Supreme People's Court upheld the Beijing IP Court ruling, confirming the validity of its semaglutide compound patent. The decision reinforces patent protection for the GLP\u20111 analogue underlying Wegovy, Ozempic, and Rybelsus in the world's second\u2011largest pharmaceutical market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52712#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52712"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52712#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp","width":1080,"height":608,"caption":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52712#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Supreme Court Upholds Novo Nordisk Semaglutide Patent Validity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52712"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52712\/revisions"}],"predecessor-version":[{"id":52719,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52712\/revisions\/52719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52718"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}